Business Context and Reporting Period
Company: Akari Therapeutics Plc
Filing Type: Form 8-K (Current Report)
Date of Report: April 5, 2024
Reporting Period: Event date April 5, 2024; references financial position as of December 31, 2023.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or operating margins. The primary financial metric disclosed is:
- Stockholders' Equity (Deficit): $229,000 deficit as of December 31, 2023.
- Listing Requirement: Minimum stockholders' equity of $2,500,000 required for continued Nasdaq listing.
Material Changes and Events
On April 5, 2024, the Company received a notice from The Nasdaq Capital Market stating it is no longer in compliance with Listing Rule 5550(b)(1) due to its stockholders' equity deficit. The filing indicates no immediate impact on the listing status of the Company's common stock.
Outlook, Risks, and Contingencies
- Compliance Timeline: The Company has 45 calendar days (until May 20, 2024) to submit a plan to regain compliance.
- Extension Possibility: If the plan is accepted, the Company may receive an extension of up to 180 calendar days (through October 2, 2024) to meet the equity requirement.
- Delisting Risk: There is no assurance the plan will be accepted or that compliance will be achieved. Failure to regain compliance could result in a delisting determination.
- Appeal Process: If delisting is determined, the Company may request a hearing before a Nasdaq Hearings Panel, which would stay the delisting action.
Investor Verification Checklist
- Verify the Company's submission of a Compliance Plan by May 20, 2024.
- Monitor Nasdaq's acceptance or rejection of the proposed Compliance Plan.
- Track the Company's stockholders' equity levels to determine if the $2,500,000 threshold is met within any granted extension period.
- Review the Annual Report on Form 10-K for the year ended December 31, 2023, for full details on the equity deficit.